The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants episode artwork

EPISODE · Nov 15, 2022 · 39 MIN

The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants

from Dementia Matters · host Wisconsin Alzheimer‘s Disease Research Center

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Show Notes Read Dr. Jason Karlawish and Dr. Josh Grill’s viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology’s June 2022 issue. Listen to our episode with Dr. Daniel Gibbs about his book (mentioned by Dr. Karlawish at 34:21) on our website, Spotify, Apple Podcasts, or wherever you listen. Listen to our past episode on amyloid disclosures with research participants on our website, Spotify, Apple Podcasts, or wherever you listen. Learn more about Dr. Josh Grill at his bio on the University of California - Irvine website. Learn more about Dr. Jason Karlawish’s work at his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Show Notes Read Dr. Jason Karlawish and Dr. Josh Grill’s viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology’s June 2022 issue. Listen to our episode with Dr. Daniel Gibbs about his book (mentioned by Dr. Karlawish at 34:21) on our website, Spotify, Apple Podcasts, or wherever you listen. Listen to our past episode on amyloid disclosures with research participants on our website, Spotify, Apple Podcasts, or wherever you listen. Learn more about Dr. Josh Grill at his bio on the University of California - Irvine website. Learn more about Dr. Jason Karlawish’s work at his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

NOW PLAYING

The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants

0:00 39:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Hyperfluent Hypio Hyperfluent transmits straight from the heart of Hyperliquid, where culture, creativity, and capital converge. Anchored by the architects of Hypio—the decentralized cultural virus—each episode archives the minds engineering the blockchain built to house all finance. These conversations are traceable artifacts in HyperEVM’s evolution: not just what’s being built, but why it matters, how it mutates, and where it’s taking us next. Listen in for the blueprints, the blind spots, and the narrative weapons shaping tomorrow’s markets.Hyperfluent: learn the language, ride the wave, spread the strain. Mobile Money by moomoo Mobile Money by moomoo Hear from seasoned traders, financial influencers, and industry insiders as they discuss money matters and market news and share their personal finance stories.Disclaimers: https://www.moomoo.com/us/support/topic4_523 Somali Motivation podcast Istahil Aideed At the heart of the Somali Motivation Podcast lies a profound mission: to uplift, inspire, and catalyze personal growth in the lives of our listeners. With a steadfast dedication to mental health awareness and domestic abuse awareness, our podcast embraces vulnerability, encourages healing, and fosters resilience within the Somali community and beyond. Through heartfelt conversations, expert insights, and shared experiences, we create a warm and welcoming space where every voice matters. Join our transformative journey as we embark on a quest to empower our community, spark meaningful change, and weave a tapestry of hope and strength. Together, we can make a difference, one episode at a time. The Up and to the Right | Small Business | Practical, Actionable, Sustainable Improvements beyond50percent Welcome to Up and to the Right, the no-nonsense podcast where we blend your passion with proven business principles and practical tips, empowering you to create the impact and success you envision.Hosted by Stephen Krausse, the show covers what matters to small business owners, startups, and people interested in becoming entrepreneurs. No buzzwords and no hyped-up trends!A graduate of Colorado State University's College of Business, Stephen has an academic background that compliments over 25 years of business operations and management experience. He started his first business as a freshman in college in 1987, recording and producing demo tapes for local bands. Since that time, he’s been involved with numerous successful small businesses, including the operation and management of a niche high-tech company with customers and suppliers worldwide.As a business professional by education and trade, he works with select business owners to blend their passion with proven principles, givi

Frequently Asked Questions

How long is this episode of Dementia Matters?

This episode is 39 minutes long.

When was this Dementia Matters episode published?

This episode was published on November 15, 2022.

What is this episode about?

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish...

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Dementia Matters episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!